Sex-Based Clinical Outcome in Advanced NSCLC Patients Undergoing PD-1/PD-L1 Inhibitor Therapy—A Retrospective Bi-Centric Cohort Study

Men with non-small cell lung cancer (NSCLC) have a more favorable response to immune-checkpoint inhibitor (ICI) monotherapy, while women especially benefit from ICI-chemotherapy (CHT) combinations. To elucidate such sex differences in clinical practice, we retrospectively analyzed two cohorts treated with either ICI monotherapy (n = 228) or ICI-CHT combination treatment (n = 80) for advanced NSCLC. Kaplan–Meier analyses were used to calculate progression-free (PFS) and overall survival (OS), influencing variables were evaluated using Cox-regression analyses. No significant sex differences for PFS/OS could be detected in either cohort. Men receiving ICI monotherapy had a statistically significant independent impact on PFS by Eastern Cooperative Oncology Group performance status (ECOG) ≥2 (hazard ratio (HR) 1.90, 95% confidence interval (CI): 1.10–3.29, p = 0.021), higher C-reactive protein (CRP; HR 1.06, 95%CI: 1.00–1.11, p = 0.037) and negative programmed death-ligand 1 (PD-L1) status (HR 2.04, 95%CI: 1.32–3.15, p = 0.001), and on OS by CRP (HR 1.09, 95%CI: 1.03–1.14, p = 0.002). In men on ICI-CHT combinations, multivariate analyses (MVA) revealed squamous histology (HR 4.00, 95%CI: 1.41–11.2, p = 0.009) significant for PFS; and ECOG ≥ 2 (HR 5.58, 95%CI: 1.88–16.5, p = 0.002) and CRP (HR 1.19, 95%CI: 1.06–1.32, p = 0.002) for OS. Among women undergoing ICI monotherapy, no variable proved significant for PFS, while ECOG ≥ 2 had a significant interaction with OS (HR 1.90, 95%CI 1.04–3.46, p = 0.037). Women treated with ICI-CHT had significant MVA findings for CRP with both PFS (HR 1.09, 95%CI: 1.02–1.16, p = 0.007) and OS (HR 1.11, 95%CI: 1.03–1.19, p = 0.004). Although men and women responded similarly to both ICI mono- and ICI-CHT treatment, predictors of response differed by sex.

Download Full-text

Sex-based Clinical Outcome in Advanced NSCLC Patients Undergoing PD-1/PD-L1 Inhibitor Therapy - a Retrospective Bi-Centric Cohort Study

10.20944/preprints202111.0447.v1 ◽

2021 ◽

Author(s):

David Lang ◽

Anna Brauner ◽

Florian Huemer ◽

Gabriel Rinnerthaler ◽

Andreas Horner ◽

...

Keyword(s):

Sex Differences ◽

Advanced Nsclc ◽

Cox Regression ◽

Group Performance ◽

Performance Status ◽

Eastern Cooperative Oncology Group ◽

Reactive Protein ◽

Kaplan Meier ◽

Predictors Of Response ◽

Treatment Predictors

Men with non-small cell lung cancer (NSCLC) have a more favorable response to immune-checkpoint inhibitor (ICI) monotherapy, while women especially benefit from ICI-chemotherapy (CHT) combinations. To elucidate such sex differences in clinical practice, we retrospectively analyzed two cohorts treated with either ICI monotherapy (n=228) or ICI-CHT combination treatment (n=80) for advanced NSCLC. Kaplan-Meier analyses were used to calculate progression-free (PFS) and overall survival (OS), influencing variables were evaluated using Cox-regression analyses. No significant sex differences for PFS/OS could be detected in either cohort. Men receiving ICI monotherapy had a statistically significant independent impact on PFS by Eastern Cooperative Oncology Group performance status (ECOG) ≥2 (hazard ratio (HR) 1.90, 95% confidence interval (CI): 1.10-3.29, p=0.021), higher C-reactive protein (CRP; HR 1.06, 95%CI: 1.00-1.11, p=0.037) and negative programmed death-ligand 1 (PD-L1) status (HR 2.04, 95%CI: 1.32-3.15, p=0.001), and on OS by CRP (HR 1.09, 95%CI: 1.03-1.14, p=0.002). In men on ICI-CHT combinations, multivariate analyses (MVA) revealed squamous histology (HR 4.00, 95%CI: 1.41-11.2, p=0.009) significant for PFS; ECOG≥2 (HR 5.58, 95%CI: 1.88-16.5, p=0.002) and CRP (HR 1.19, 95%CI: 1.06-1.32, p=0.002) for OS. Among women undergoing ICI monotherapy, no variable proved significant for PFS, ECOG≥2 had a significant interaction with OS (HR 1.90, 95%CI 1.04-3.46, p=0.037). Women treated with ICI-CHT had significant MVA findings for CRP with both PFS (HR 1.09, 95%CI: 1.02-1.16, p=0.007) and OS (HR 1.11, 95%CI: 1.03-1.19, p=0.004). Although men and women responded similarly to both ICI mono- and ICI-CHT treatment, predictors of response differed by sex.

Download Full-text

Adjuvant treatment in older patients with rectal cancer: a population-based review

Current Oncology ◽

10.3747/co.25.4102 ◽

2018 ◽

Vol 25 (6) ◽

Cited By ~ 2

Author(s):

S. L. Liu ◽

P. O’Brien ◽

Y. Zhao ◽

W. M. Hopman ◽

N. Lamond ◽

...

Keyword(s):

Rectal Cancer ◽

Older Patients ◽

Cox Regression ◽

Group Performance ◽

Performance Status ◽

Eastern Cooperative Oncology Group ◽

Neoadjuvant Chemoradiation ◽

Oncology Group ◽

Cox Regression Analysis ◽

Kaplan Meier

Background Little is known about the benefits of adjuvant chemotherapy (adj) in the older population with locally advanced rectal cancer (larc). We evaluated use of adj, survival outcomes, and adj-related toxicity in older patients with larc.Methods Our retrospective review included 286 patients with larc (stages ii and iii) diagnosed between January 2010 and December 2013 in Nova Scotia who underwent curative-intent surgery. Baseline patient, tumour, and treatment characteristics were collected. The survival analysis used the Kaplan–Meier method and Cox regression statistics.Results Of 286 identified patients, 152 were 65 years of age or older, and 92 were 70 years of age or older. Median follow-up was 46 months, and 163 patients (57%) received neoadjuvant chemoradiation. Although adj was given to 81% of patients (n = 109) less than 65 years of age, only 29% patients (n = 27) 70 years of age and older received adj. Kaplan–Meier analysis suggested a potential survival advantage for adj regardless of age. In multivariate Cox regression analysis, Eastern Cooperative Oncology Group performance status, T stage, and adj were significant predictors of overall survival (p < 0.04); age was not. Similarly, N stage, neoadjuvant chemoradiation, and adj were significant predictors of disease-free survival (p < 0.01). Poor Eastern Cooperative Oncology Group performance status was the most common cause of adj omission. In patients 70 years of age and older, grade 1 or greater chemotherapy-related toxicities were experienced significantly more often by those treated with adj (85% vs. 68% for those not treated with adj, p < 0.05).Conclusions Regardless of age, patients with larc seem to experience a survival benefit with adj. However, older patients are less likely to receive adj, and when they do, they experience more chemotherapy-related toxicities.

Download Full-text

Myosteatosis as a novel prognostic biomarker after radical cystectomy for bladder cancer

Scientific Reports ◽

10.1038/s41598-020-79340-9 ◽

2020 ◽

Vol 10 (1) ◽

Author(s):

Shimpei Yamashita ◽

Yuya Iwahashi ◽

Haruka Miyai ◽

Takashi Iguchi ◽

Hiroyuki Koike ◽

...

Keyword(s):

Bladder Cancer ◽

Radical Cystectomy ◽

Cox Regression ◽

Group Performance ◽

Performance Status ◽

Eastern Cooperative Oncology Group ◽

Psoas Muscle ◽

Hounsfield Units ◽

Computed Tomography Images ◽

Psoas Muscles

AbstractThis study aims to evaluate the influence of myosteatosis on survival of patients after radical cystectomy (RC) for bladder cancer. We retrospectively identified 230 patients who underwent RC for bladder cancer at our three institutions between 2009 and 2018. Digitized free-hand outlines of the left and right psoas muscles were made on axial non-contrast computed tomography images at level L3. To assess myosteatosis, average total psoas density (ATPD) in Hounsfield Units (HU) was also calculated as an average of bilateral psoas muscle density. We compared cancer-specific survival (CSS) between high ATPD and low ATPD groups and performed cox regression hazard analyses to identify the predictors of CSS. Median ATPD was 44 HU (quartile: 39–47 Hounsfield Units). Two-year CSS rate in overall patients was 76.6%. Patients with low ATPD (< 44 HU) had significantly lower CSS rate (P = 0.01) than patients with high ATPD (≥ 44 HU). According to multivariate analysis, significant independent predictors of poor CSS were: Eastern Cooperative Oncology Group performance status ≥ 1 (P = 0.03), decreasing ATPD (P = 0.03), non-urothelial carcinoma (P = 0.01), pT ≥ 3 (P < 0.01), and pN positive (P < 0.01). In conclusion, myosteatosis (low ATPD) could be a novel predictor of prognosis after RC for bladder cancer.

Download Full-text

Influence of tumor size and Eastern Cooperative Oncology Group performance status (ECOG PS) at baseline on patient (pt) outcomes in lenvatinib-treated radioiodine-refractory differentiated thyroid cancer (RR-DTC).

Journal of Clinical Oncology ◽

10.1200/jco.2019.37.15_suppl.6081 ◽

2019 ◽

Vol 37 (15_suppl) ◽

pp. 6081-6081 ◽

Cited By ~ 3

Author(s):

Lori J. Wirth ◽

Sophie Leboulleux ◽

Naomi Kiyota ◽

Makoto Tahara ◽

Kei Muro ◽

...

Keyword(s):

Tumor Size ◽

Group Performance ◽

Performance Status ◽

Objective Response ◽

Eastern Cooperative Oncology Group ◽

Progression Free Survival ◽

Disease Characteristics ◽

Kaplan Meier ◽

Ecog Ps ◽

Post Hoc

6081 Background: In SELECT, lenvatinib significantly improved progression-free survival (PFS) of pts with RR-DTC versus placebo (18.3 v 3.6 months; hazard ratio [HR]: 0.21 [99% CI: 0.14, 0.31]; P<0.001). Here we examine the treatment of RR-DTC with lenvatinib in relation to tumor size (sum of all targeted lesions) and ECOG PS. Methods: In this post hoc analysis of SELECT with pts randomized to receive lenvatinib, Kaplan-Meier estimates of time to ECOG PS ≥2 were calculated for subgroups of pts according to baseline ECOG PS or tumor size. Objective response rate (ORR) and Kaplan-Meier estimates of overall survival (OS) and PFS according to ECOG PS (0 or 1) at baseline were calculated. Correlations between ECOG PS at baseline (0 or 1) and maximum tumor shrinkage were calculated using one-way analysis of variance. Results: Pts with ECOG PS 0 or 1 at baseline had similar demographic and disease characteristics. ORR was 78.5% and 51.0% for pts with ECOG PS 0 and 1 at baseline, respectively (odds ratio [95% CI]: 3.508 [2.018, 6.097]). Mean maximum percent decrease in tumor size was significantly greater in pts with baseline ECOG PS 0 (-46.13%) versus pts with ECOG PS 1 (-37.16%; P=0.0017). For pts with ECOG PS 1 at baseline, time to ECOG PS ≥2 was numerically shorter with tumor size >60 mm versus tumor size ≤60 mm (HR [95% CI]: 1.450 [0.708, 2.967]). Additional results are summarized in the table. Conclusions: Among pts with RR-DTC, PFS, OS, ORR, and time to ECOG ≥2 were generally better for patients with lower ECOG PS or smaller tumor size at baseline. These results may indicate that it is beneficial to start lenvatinib in pts with RR-DTC early, before ECOG PS worsens and tumor size increases. Clinical trial information: NCT01321554. [Table: see text]

Download Full-text

A genomic-clinical nomogram predicting recurrence-free survival for patients diagnosed with hepatocellular carcinoma

PeerJ ◽

10.7717/peerj.7942 ◽

2019 ◽

Vol 7 ◽

pp. e7942

Author(s):

Junjie Kong ◽

Tao Wang ◽

Shu Shen ◽

Zifei Zhang ◽

Xianwei Yang ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Risk Model ◽

Cox Regression ◽

Group Performance ◽

Performance Status ◽

Survival Rates ◽

Eastern Cooperative Oncology Group ◽

Staging System ◽

Recurrence Free Survival ◽

Free Survival

Liver resection surgery is the most commonly used treatment strategy for patients diagnosed with hepatocellular carcinoma (HCC). However, there is still a chance for recurrence in these patients despite the survival benefits of this procedure. This study aimed to explore recurrence-related genes (RRGs) and establish a genomic-clinical nomogram for predicting postoperative recurrence in HCC patients. A total of 123 differently expressed genes and three RRGs (PZP, SPP2, and PRC1) were identified from online databases via Cox regression and LASSO logistic regression analyses and a gene-based risk model containing RRGs was then established. The Harrell’s concordance index (C-index), receiver operating characteristic (ROC) curves and calibration curves showed that the model performed well. Finally, a genomic-clinical nomogram incorporating the gene-based risk model, AJCC staging system, and Eastern Cooperative Oncology Group performance status was constructed to predict the 1-, 2-, and 3-year recurrence-free survival rates (RFS) for HCC patients. The C-index, ROC analysis, and decision curve analysis were good indicators of the nomogram’s performance. In conclusion, we identified three reliable RRGs associated with the recurrence of cancer and constructed a nomogram that performed well in predicting RFS for HCC patients. These findings could enrich our understanding of the mechanisms for HCC recurrence, help surgeons predict patients’ prognosis, and promote HCC treatment.

Download Full-text

Does NSCLC patient-rated performance status predict survival more accurately than physician ratings?

Journal of Clinical Oncology ◽

10.1200/jco.2007.25.18_suppl.9022 ◽

2007 ◽

Vol 25 (18_suppl) ◽

pp. 9022-9022 ◽

Cited By ~ 1

Author(s):

E. Dajczman ◽

G. Kasymjanova ◽

N. Swinton ◽

D. St-Pierre ◽

T. Swanson ◽

...

Keyword(s):

Survival Analysis ◽

Cox Regression ◽

Performance Status ◽

Nsclc Patient ◽

Eastern Cooperative Oncology Group ◽

Activity Level ◽

Rank Test ◽

Kaplan Meier ◽

Signed Rank ◽

Signed Rank Test

9022 Background: The Eastern Cooperative Oncology Group (ECOG) score is a well known predictor of survival, which impacts on treatment decisions. Patient (pt) rated activity level, using the Patient Generated Subjective Global Assessment (PG-SGA) scale, is identical in criteria to the ECOG scale used by physicians. We compared the patient rated activity level (Pt-PS) to physician rated PS (MD-PS), at baseline, and evaluated survival with respect to the 2 PS ratings. Methods: Pts with newly diagnosed advanced NSCLC (stages 3–4) completed a PG-SGA self rated questionnaire, which was then compared to the physician-generated ECOG score recorded prior to any treatment using a Wilcoxon signed rank test. Pts were treated with standard chemotherapy. Survival analysis was performed using a Kaplan Meier analysis and Cox regression. Results: 92 pts (M: F-48:44) with a mean age of 65 years (39–83) were included. 67 (73%) presented with stage 4 disease. 62 (67%) had an MD-PS of 0–1, whereas only 51 (55%) had a Pt-PS of 0 -1. MD-PS 3–4 was seen in 9 (10%), compared to 28 (30%) by Pt-PS. Pt-PS was significantly different from MD-PS in 48% of scores (p=0.003). When scores were not congruent, 29/44 (66%) pts evaluated themselves as having a worse PS than the physician. Survival analysis demonstrated that stage and functional status irrespective of method of reporting was predictive of survival (p=0.01 for MD-PS and p=0.001 for Pt-PS). However, when comparing median survival by method of performance status evaluation, Pt-PS was associated with superior stratification of survival than MD-PS ( table 1 ). Conclusions: Pt-PS and MD-PS are not congruent almost 50% of the time. Pt-PS allows for better stratification of survival and should be further evaluated in prospective trials. No significant financial relationships to disclose. [Table: see text]

Download Full-text

Patient-Centered Approach to Benefit–Risk Characterization Using Number Needed to Benefit and Number Needed to Harm: Advanced Non–Small-Cell Lung Cancer

JCO Clinical Cancer Informatics ◽

10.1200/cci.19.00103 ◽

2020 ◽

pp. 769-783

Author(s):

Gokaraju K. Raju ◽

Sean Khozin ◽

Karthik Gurumurthi ◽

Reuben Domike ◽

Janet Woodcock

Keyword(s):

Advanced Nsclc ◽

Group Performance ◽

Performance Status ◽

Eastern Cooperative Oncology Group ◽

Growth Factor Receptor ◽

Medical Practitioners ◽

Programmed Death ◽

Programmed Death 1 ◽

Epidermal Growth ◽

Number Needed To Harm

This work summarizes the benefit and risk of the results of clinical trials submitted to the US Food and Drug Administration of therapies for the treatment of non–small cell lung cancer (NSCLC) using number needed to benefit (NNB) and number needed to harm (NNH) metrics. NNB and NNH metrics have been reported as potentially being more patient centric and more intuitive to medical practitioners than more common metrics, such as the hazard ratio, and valuable to medical practitioners in complementing other metrics, such as the median time to event. This approach involved the characterization of efficacy and safety results in terms of NNB and NNH of 30 clinical trials in advanced NSCLC supporting US Food and Drug Administration approval decisions from 2003 to 2017. We assessed trends of NNB over time of treatment (eg, for programmed death 1 inhibitors) and variation of NNB across subpopulations (eg, characterized by epidermal growth factor receptor mutation, programmed death ligand 1 expression, Eastern Cooperative Oncology Group performance status, age, and extent of disease progression). Furthermore, the evolution of NNB of treatments for advanced NSCLC was charted from 2003 to 2017. Across subpopulations, NNB, on average, was 4 patients for approved targeted therapies in molecularly enriched populations, 11 patients for approved therapies in nonmolecularly enriched populations, and 23 patients for withdrawn or unapproved therapies. Furthermore, the NNB analysis showed variation for attributes of epidermal growth factor receptor mutations, level of programmed death 1 expression, Eastern Cooperative Oncology Group performance status, etc. When considering the best-case subpopulations and available drugs, the NNB frontier reduced from an estimated value of 7.7 in 2003 to an estimated value of 2.5 in 2017 at the estimated median overall survival—equal to 6 months—of an untreated patient.

Download Full-text

Pomalidomide, Bortezomib, and Dexamethasone (PVd) for Chinese Multiple Myeloma Patients at First Relapse

Blood ◽

10.1182/blood-2021-147749 ◽

2021 ◽

Vol 138 (Supplement 1) ◽

pp. 4781-4781

Author(s):

Lugui Qiu ◽

Gang An

Keyword(s):

Multiple Myeloma ◽

Peripheral Neuropathy ◽

Group Performance ◽

Conflicts Of Interest ◽

Performance Status ◽

Eastern Cooperative Oncology Group ◽

Chinese Patients ◽

Kaplan Meier ◽

First Relapse ◽

Grade 3

Abstract Background: The phase 3 OPTIMISMM（NCT01734928） trial done at 133 hospitals and research centres in 21 countries but no Chinese site involved in this study. In the OPTIMISMM study ,pomalidomide, bortezomib, and dexamethasone (PVd) demonstrated excellent efﬁcacy in patients at ﬁrst relapse, including immediately after upfront lenalidomide treatment failure and other common ﬁrst-line treatments, the mPFS was 20.73 months, the ORR was 90.1%, and no new safety signals were observed. Building on these promising results, we decided to explore PVd in Chinese patients at ﬁrst relapse. Study Design/Methods: This is a multicenter, prospective, single-arm phase 2 study designed to evaluate the efﬁcacy and safety of PVd in Chinese patients at ﬁrst relapse. Eligible patients were aged ≥18 years and had a diagnosis of multiple myeloma, measurable disease, and an Eastern Cooperative Oncology Group performance status of 0-2. Patients were required to have had only 1 prior antimyeloma regimen. Key exclusion criteria included creatinine clearance<30 mL/min requiring dialysis, grade ≥3 peripheral neuropathy, or grade 2 peripheral neuropathy with pain. Patients with prior exposure to bortezomib were eligible, provided they were not refractory to a bortezomib-containing regimen dosed at 1.3 mg/m 2 twice weekly. Patient（n=62,Figure 1）will receive pomalidomide 4 mg on days 1-14 of each cycle. Bortezomib 1.3 mg/m 2 on days 1, 4, 8, and 11 of cycles 1-8 and on days 1 and 8 of cycles 9 and beyond. Dexamethasone was given on days 1, 2, 4, 5, 8, 9, 11, and 12 of cycles 1-8 and on days 1, 2, 8, and 9 of cycles 9 and beyond; patients received 20 mg of dexamethasone if aged ≤75 years and 10 mg otherwise. The primary endpoint is ORR, the secondary endpoints are≥VGPR, MRD(-) rate, PFS, OS and safety. ORR will be assessed by the International Myeloma Working Group criteria after each cycle until PD. The Kaplan-Meier method will be used to estimate PFS and OS. Safety analysis will be conducted in the safety population, which are composed of all patients who received ≥1 dose of study medication. The trial is currently enrolling and will be open in 7 sites of China. Disclosures: Research Sponsor: CHIATAI TIANQING PHARMACEUTICAL GROUP. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.

Download Full-text

Long-term survival of patients with metastatic renal cell carcinoma (mRCC) treated with targeted therapy (TT) without cytoreductive nephrectomy (CN).

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.7_suppl.346 ◽

2011 ◽

Vol 29 (7_suppl) ◽

pp. 346-346

Author(s):

S. L. Richey ◽

S. H. Culp ◽

E. Jonasch ◽

P. G. Corn ◽

L. C. Pagliaro ◽

...

Keyword(s):

Primary Tumor ◽

Group Performance ◽

Performance Status ◽

Eastern Cooperative Oncology Group ◽

Outcome Data ◽

Term Survival ◽

Long Term Survival ◽

Kaplan Meier ◽

Targeted Agent

346 Background: We recently reported on 188 patients (pts) with mRCC treated with TT without CN [Richey et al, J Clin Oncol 28:15s, 2010 (suppl; abstr 4613); Annals of Oncology- in press]. We report here outcome data on pts who survived > 24 months (mos). Methods: We retrospectively reviewed records of patients with mRCC who received TT without CN and survived longer than 24 mos from treatment initiation. Pts did not undergo CN due to medical comorbidity, unresectable primary tumor, heavy disease burden, or patient preference. Kaplan-Meier methods were used to estimate median overall survival (OS). Long-term complications related to therapy were evaluated. Results: 22 pts were identified meeting the inclusion criteria. Median follow-up was 30.4 mos (range, 24.1- 68.7), with median OS time of 34.1 mos (95% CI: 30.2, 37.2). Median time on therapy (TOT) was 25.3 mos (IQR: 13.7, 28.5). Six pts (27.3%) were alive at the time of analysis, with median TOT of 26.9 mos (range: 13.7, 62.5) (IQR: 24.6, 33.4). Eastern Cooperative Oncology Group performance status was 0 or 1 in 86% of pts. Ten (45%) and 12 (55%) pts had intermediate- and poor-risk disease by Heng et al criteria (JCO 2009), respectively. Patients received the following types of TT: sunitinib 14 (63.6%), sorafenib 13 (59.1%), temsirolimus 5 (22.7%), bevacizumab 5 (22.7%), pazopanib 3 (13.6%), everolimus 4 (18.2%), erlotinib 3 (13.6%), investigational targeted agent 1 (4.6%). Four (18.2%), 5 (22.7%), and 13 (59.1%) pts received 1, 2, or ≥ 3 different therapies, respectively. During treatment with TT, 6 pts (27.3%) developed hypertension, 6 pts (27.3%) developed hypothyroidism, 2 pts (9.1%) developed congestive heart failure, 1 pt (4.6%) developed stroke. No pts developed bleeding or myocardial infarction. By radiographic assessment of best primary tumor response, 4 (18.2%) pts had a partial response (≥30% decrease), 10 (45.5%) exhibited a decrease <30%, and 6 (27.3%) had stable or increased size of the primary tumor. Conclusions: These data highlight the potential for long-term survival of patients with mRCC treated with TT without CN, and underscore the challenges in managing therapy-related long-term adverse events. No significant financial relationships to disclose.

Download Full-text

Clinical analysis of ECOG PS and adverse reactions in patients with anlotinib at advanced NSCLC as the third or further line treatment: a retrospective observational study

10.21203/rs.3.rs-97666/v1 ◽

2020 ◽

Author(s):

wei guo gu ◽

MingBin Hu ◽

JianXiong Deng ◽

Feng Qiu

Keyword(s):

Adverse Reactions ◽

Advanced Nsclc ◽

Group Performance ◽

Remission Rate ◽

Performance Status ◽

Eastern Cooperative Oncology Group ◽

Lung Squamous Cell Carcinoma ◽

Clinical Analysis ◽

Line Treatment ◽

Ecog Ps

Abstract Background: Previous studies have shown that anlotinib be a decent choice in third- or futher line treatment of advanced NSCLC. However, the study anslysis of relationship between Eastern Cooperative Oncology Group performance status(ECOG PS) and adverse reactions in advanced NSCLC with anlotinib therapy is less. Methods: We evaluated the efficacy and toxicity of anlotinib in patients with previously treated advanced NSCLC from June 2018 to March 2019. Survival analysis was performed by the Kaplan–Meier method.Results: According to ECOG PS devided into PS 0-1 group(n=63) and PS 2 group(n=28) . The PS 0-1 of median progression-free survival (mPFS, 5.5 vs.2.7 months, P＜0.05) , overall survival (mOS, 9.2 vs.4.7 months，P＜0.05) was longer than PS 2. The PS 0-1 of objective remission rate(ORR, 45.1% vs 6.6%), disease control rate(DCR, 8.8% vs 1.1%) was significanly more than PS 2. The PS 0-1 group of I-II adverse reactions was high than PS 2 group(52.3% vs 32.1%), but the III-IV adverse reactions were less than PS 2 group(9.5% vs 10.7%). Moreover, multivariate analysis indicated that PS was independent risk factor of PFS（HR=2.816, 95%CI：1.661-4.773，P<0.0001）as well as OS(HR=3.188, 95%CI：1.789-5.682，P=0.0001) for anlotinib therapy in NSCLC. Conclusions: Patients in advanced NSCLC with PS 0–1 get better PFS and OS than PS 2 followed by anlotinib treatment in NSCLC. Advanced lung squamous cell carcinoma(LUSC) recived anlotinib treatment with the same efficacy comparable to adenocarcinoma, and patients with PS 0-1 may benefit the most than PS 2.

Download Full-text